Abstract
Many factors must be considered for the effective and safe use of cyclosporin A (CsA) in paediatric nephrology. Detailed knowledge of the variable bioavailability, tissue distribution, and metabolism, as well as causes which lead to their alteration are necessary. Factors which affect the activity of the mixed function oxidase system cytochrome P-450 must be considered, i. e. liver dysfunction and many drugs. Precise knowledge of the CsA determination method and the spectrum of metabolites is essential. In children with renal transplants, a body surface area-related dose will better meet the dose requirements than a body weight related-dose. For drug level monitoring whole blood rather than plasma should be used, and the parent drug level should be the main determinant; elevated metabolite levels may be important in suspected nephrotoxicity or liver dysfunction. Pharmacokinetic profiles are necessary to discover absorption problems or increased CsA clearance rates which necessitate shorter dosing intervals. In children with steroid-dependent minimal change nephrotic syndrome, remission without steroids is maintained as long as CsA is given. The appropriate starting dosage is 150 mg/m2 per day; trough level monitoring is mandatory to prevent nephrotoxicity and to confirm adequate immunosuppressive drug levels which should be 80–160 ng/ml (parent drug level). Although the benefit of CsA has been reported in some cases of lupus erythematosus, its use should be restricted to severe cases only until its efficacy and safety has been confirmed in controlled trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Borel JF, Feurer C, Gubler HU, Stähelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468–475
Borel FJ (1989) The cyclosporins. Transplant Proc 21: 810–815
Petcher TJ, Weber HP, Rügger A (1976) Crystal and molecular structure of an iodo-derivate of the cyclic undecapeptide cyclosporin A. Helv Chim Acta 59: 1480–1488
Sandoz, Basel (1990) Postmarketing surveillance
Mason J (1990) The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 4: 554–574
Grevel J, Kahan B (1989) Pharmacokinetics of cyclosporin A. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Dordrecht, pp 252–266
Grevel J (1986) Absorption of cyclosporin A after oral dosing. Transplant Proc 18 [Suppl 5]: 9–15
Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR (1985) The effect of food on cyclosporine absorption. Transplantation 40: 174–176
Canafax DM, Cipolle RJ, Hrushesky WJM, Rabatin JT, Min DI, Graves NM, Sutherland DER, Bowers LD (1988) The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 20 [Suppl 2]: 471–477
Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL (1990) Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 322: 733–738
Nashan B, Bleck J, Wonigeit K (1988) Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 20 [Suppl 2]: 637–639
Wagner O, Schreier E, Heitz F, Maurer G (1987) Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 15: 377–383
Beveridge T (1982) Pharmacokinetics and metabolism of cyclosporin A. In: White DJG (ed) Cyclosporin A: Proceedings of an International Conference on Cyclosporin A. Elsevier, Amsterdam, pp 35–44
Follath F, Wnk M, Vozeh S (1983) Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34: 638–643
Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15: 446–453
Maurer G (1985) Metabolism of cyclosporine. Transplant Proc 17 [Suppl 1]: 19–26
Maurer G, Lemaire M (1986) Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 18 [Suppl 5]: 25–34
Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34: 715–718
Atkinson K, Britton K, Biggs J (1984) Distribution and concentration of cyclosporin in human blood. J Clin Pathol 37: 1167–1171
Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O (1983) Distribution and binding of cyclosporin in blood and tissue. Transplant Proc 15: 2419–2421
Gurecki J, Warty V, Sanghvi A (1985) The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 17: 1997–2002
Bellitsky P, Ghose T, Givner M, Rowden G, Pope B (1985) Tissue distribution of cyclosporin A in the mouse: a clue to toxicity? Clin Nephrol 25 [Suppl 1]: 27–29
Backman L, Brandt I, Dallner G, Ringden O (1988) Tissue distribution of (3H)cyclosporine in mice. Transplant Proc 20 [Suppl 2]: 684–691
Burckart GJ, Venkataramanan R, Starzl TE, Ptachcinski RJ, Gartner CJ, Rosenthal T (1984) Cyclosporine clearance in children following organ transplantation. J Clin Pharmacol 24: 412–416
Venkataramanan R, Burckart GJ, Ptachcinski RJ (1985) Pharmacokinetics and monitoring of cyclosporin following orthotopic liver transplantation. Semin Liver Dis 5: 357–368
Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ (1986) Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40: 438–443
Rosano TG, Freed BM, Cerilli J, Lempert N (1986) Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation 42: 262–266
Maurer G, Loosli HR, Schreier E, Keller B (1984) Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos 12: 120–126
Quesniaux VFJ (1989) Pharmacology of cyclosporine (Sandimmune). III. Immunochemistry and monotoring. Pharmacol Rev 41: 249–258
Cheung F, Wong PY, Loo J, Cole EH, Levy GA (1988) Identification of cyclosporine metabolites in human bile, blood, and urine by high-performance liquid chromatography/radioimmunoassay/fast atomic bombardment mass spectroscopy. Transplant Proc 20 [Suppl 2]: 602–608
Freed BM, Rosano TG, Lempert N (1987) In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation 43: 123–127
Schlitt HJ, Christians U, Bleck J, Kohlhaw K, Ringe B, Bunzendahl H, Sewing KF, Wonigeit K, Pichlmayr R (1991) Contribution of cyclosporin metabolites to immunosuppression in liver-transplanted patients with severe graft dysfunction. Transplant Int 4: in press
Rosano TG, Freed BM, Fell MA, Lempert N (1986) Cyclosporine metabolites in human blood and renal tissue. Transplant Proc 18 [Suppl 5]: 35–40
Zeevi A, Eiras G, Burckart G, Makowka L, Venkataramenan R, Wang C, Van Thiel DH, Murase N, Starzl T, Duquesnoy R (1988) Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplant Proc 20 [Suppl 2]: 115–121
Chabannes D, Moreau JF, Soulillou JP (1987) Effect of cyclosporine, cyclosporine metabolite 17, and other cyclosporine-related compounds on T lymphocyte clones derived from rejected human kidney grafts. Transplantation 44: 813–817
Freed BM, Rosano TG, Quick C, Lempert N (1987) Effects of cyclosporine metabolites M17 and M18 on proliferation and IL-2 production in the mixed lymphocyte culture. Transplant Proc 19: 1223–1226
Ryffel B, Foxwell BMJ, Mihatsch MJ, Donatsch P, Maurer G (1988) Biologic significance of cyclosporine metabolites. Transplant Proc 20 [Suppl 2]: 575–584
Lensmeyer G, Wiebe D, Calson I (1988) Deposition of nine metabolites of cyclosporine in human tissues, bile urine and whole blood. Transplant Proc 20 [Suppl 2]: 614–622
Leunissen K, Bosman F, Beuman G, Hoof J van (1988) The nephrotoxic effects of cyclosporine metabolites. Transplant Proc 20 [Suppl 3]: 738–739
Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N (1988) Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc 20 [Suppl 2]: 330–338
Roberts NB, Lane C, Scott MH, Sells RA (1988) The measurement of cyclosporin A and metabolite M17 in whole blood by high performance liquid chromatography. Transplant Proc 20 [Suppl 2]: 625–632
Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R (1990) Cyclosporin monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 22: 1305–1311
Cockburn I, Krupp P (1989) Sandimmun—an appraisal of drug interactions. In: Andreucci VE, Del Canton A (eds), Current therapy in nephrology. Kluwer, Boston pp 503–518
Scott JPP, Higenbottam TW (1988) Adverse reactions and interactions of cyclosporin. Med Toxicol 3: 107–127
Burke MD, McIntyre F, Cameron D, Whiting PH (1989) Cyclosporin A metabolism and drug interactions. In: Thomson AW (ed) Cyclosporin, mode of action nd clinical applications. Kluwer, Dordrecht, pp 267–302
Ptachcinski RJ, Venkatarmanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107–132
Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 38: 304–306
Rowland M, Gupta SK (1987) Cyclosporin-phenytoin interaction: reevaluation using metabolite data. Br J Clin Pharmacol 24: 329–334
Schwass DE, Sasaki AW, Houghton DC, Benner KE, Bennett WM (1985) Effect of phenobarbital and cimetidine on experimental cyclosporine nephrotoxicity: preliminary observations. Clin Nephrol 25 [Suppl 1]: 117–120
Daniels NJ, Dover JS, Schachter RK (1984) Interaction between cyclosporin and rifampicin. Lancet II: 639
Allen RD, Hunnisett AG, Morris PJ (1985) Cyclosporin and rifampicin in renal transplantation. Lancet I: 980
Langhoff E, Madsen S (1983) Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment. Lancet II: 1031
Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 38: 304–305
Freeman DJ, Laupacis A, Keown PA, Stiller C, Carruthers SG (1984) Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 18: 887–893
Wood AJ, Maurer G, Niederberger W, Beveridge T (1983) Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 15 [Suppl 1]: 2409–2412
Carstensen H, Jacobsen N (1986) Interaction between cyclosporin A and phenobarbitone. Br J Clin Pharmacol 21: 550–551
Lele P, Peterson P, Yang S, Jarrell B, Burke JF (1985) Cyclosporine and tegretal—another drug interaction. Kidney Int 27: 344
Durrant S, Chipping PM, Palmer S, Gordon-Smith EC (1982) Cyclosporin A methylprednisolone and convulsions. Lancet II: 829–830
Boogaerts MA, Zachee P, Verwilghen RL (1982) Cyclosporine, methyl-prednisolone and convulsions. Lancet II: 1217
Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal JT (1985) Effect of erythromycin on cyclosporine levels. N Engl J Med 313: 1416–1417
Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J (1986) The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 104: 660–661
Hourmant M, Le Bigot JF, Vernillet L, Sagniez G, Remi JP, Soulillou JP (1985) Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 17: 2723–2727
D'Soza MJ, Pollock SH, Solomon HM (1988) Cyclosporinecimetidine interaction. Drug Metab Dispos 16: 57–59
Babany G, Morris RE, Babany I, Shepherd S, Kates RE (1988) Effects of the administration of cimetidine or phenobarbital on the immunosuppression of cyclosporine in mice in vivo. Transplant Proc 20
Freeman DJ, Laupacis A, Keown P, Stiller C, Carruthers G (1984) The effect of agents that alter drug metabolising enzyme activity on the pharmacokinetics of cyclosporine. Ann R Coll Phys Surg Can 17: 301
White DJG, Blatchford NR, Cauwenbergh G (1984) Cyclosporine and ketoconazole. Transplantation 37: 214–215
Gumbleton M, Brown JE, Hawksworth G, Whiting PH (1985) The possible relationship between heptic drug metabolism and ketoconazole enhancement of cyclosporine A-nephrotoxicity. Transplantation 46: 454–456
Dieperink H, Moller J (1982) Ketoconazole and cyclosporin. Lancet II: 1217
Ferguson RM, Sutherland DFR, Simmons RL, Najarian JS (1982) Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet II: 882–883
Grino JM, Sabate I, Castelao AM, Alsina J (1986) Influence of diltiazem on cyclosporin clearance. Lancet I: 1387
Pochet JM, Pirson Y (1986) Cyclosporin-diltiazem interaction. Lancet I: 979
Neumayer HH, Wagner K (1986) Diltiazem and economic use of cyclosporin. Lancet II: 523
Ross WB, Roberts D, Griffin PJA, Salaman JR (1986) Cyclosporin interaction with danazol and norethisterone. Lancet I: 330
Schroder O, Schmitz N, Kayser W, Euler HH, Loffler H (1986) Erhöhte Ciclosporin-A-Spiegel bei gleichzeitiger Therapie mit danazol. D Med Wochenschr 111: 602–603
Whiting PH, Cunningham C, Thomson AW, Simpson JG (1984) Enhancement of high dose cyclosporin A toxicity by frusemide. Biochem Pharmacol 33: 1075–1079
Fabre I, Fabre G, Maurel G, Bertault-Peres P, Cano JP (1988) Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions. Drug Metab Dispos 16: 296–301
Wallwork J, McGregor CGA, Wells FC, Cory-Pearce R, English TAH (1983) Cyclosporin and intravenous sulphadimidine and trimethoprim therapy. Lancet I: 366–367
Jones DK, Hakim M, Wallwork J, Higenbottam TW, White DJG (1986) Serious interaction between cyclosporin A and sulphadimidine. BMJ 292: 728–729
Termeer A, Hoitsma AJ, Koene RAP (1986) Severe nephrotoxicity caused by the combined use of gentamycin and cyclosporin in renal allograft recipients. Transplantation 42: 220–221
Burke MD, Whiting PH (1986) The role of drug metabolism in cyclosporine A nephrotoxicity. Clin Nephrol 25 [Suppl 1]: 111–116
Tobert JA (1988) Correspondence. N Engl J Med 318: 48
Bohnhorst B, Offner G, Albers N, Beier CJ (1990) Gingivahyperplasie bei nierentransplantierten Patienten. Monatsschr Kinderheilk 138: 568
McCauley J, Fung J, Jain A, Todo S, Starzl TE (1990) The effect of FK 506 on renal function after liver transplantation. Transplant Proc 22 (suppl 1): 17–20
Argawal RP, McPherson RA, Threatte GA (1985) Assessment of cyclosporin A in whole blood and plasma of five patients with different hematocrits. Ther Drug Monit 7: 61–65
Rosano TG (1985) Effect of hematocrit on cyclosporine (cycloporin-A) in whole blood and plasma of renal-transplant patients. Clin Chem 31: 410–412
Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring (1987). Clin Chem 33: 1269–1288
Donatsch P, Abisch E, Homberger M, Traber R, Trapp M, Voges R (1981) A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay 2: 19–32
Holt DW, Marsden JJ, Johnston A (1986) Measurement of cyclosporin A: methodological problems. J Immunoassay [Suppl] 18: 101–110
Niederberger W, Schaub P, Johnston A (1980) High performance liquid chromatographic determination of cyclosporin A in plasma and urine. J Chromatogr 182: 454–458
Christians U, Schlitt H, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer SS, Schottmann R, Wonigeit K, Pichlmayr R, Sewing, K-F (1988) Measurement of cyclosporine and 18 metabolites in blood bile and urine by high performance liquid chromatography. Transplant Proc 20 [Suppl 2]: 609–613
Pesce AJ, Schroeder TJ, First MR (1990) An evaluation of cyclosporine monitoring by non-selective fluorescence polarization immunoassay. Transplant Proc 22: 1171–1174
Yatscoff RW, Copeland KR, Faraci CJ (1990) Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 36: 1969–1973
Karol R (1990) A rapid and specific whole blood cyclosporine assay for the DuPont aca discrete clinical analyzer. Du Pont, Glasgow
Beresini M, Toton-Quinn R, Barnett B, Davalian D, Berger E, Hu M, Blohm B, Alexander L, Cerelli MJ (1990) Emit cyclosporine assay for whole blood samples on the COBAS MIRA analyzer. Syva, Palo Alto
Grevel J, Welsh M, Kahan BD (1989) Cyclosporine monitoring in renal transplantation: AUC monitoring is superior to trough level monitoring. Ther Drug Monit 11: 246–248
Alexander SR, Arbus GS, Butt KMH, Conley S, Fine RN, Greifer I, Gruskin AB, Harmon WE, McEnery PT, Nevins TE, Nogueira N, Salvatierra O Jr, Tejani A (1990) The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 4: 542–553
Hoyer PF (1989) Optimal use of cyclosporin A in children. Pediatr Nephrol 3: C83
Canafax MD, Min DI, Matas AJ, Amend WJC, Ptachinsksi RJ, Hakala TR, Grevel J, Houghton D, Kahan BD, Simmons RL, Najarian JS, Cipolle RJ (1990) Effects of initial cyclosporine dose and timing on long-term creatinine levels in cadaver renal transplantation. Clin Transplant 4: 321–328
Broyer M, Niaudet P, Gagnadoux MF, Guest G, Dechaux M, Habib R, Beurton D (1989) Results obtained with different immunosuppressive (IS) protocols after kidney transplantation in children. Pediatr Nephrol 3: C84
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323: 1723–1728
Hoyer PF, Offner G, Wonigeit K, Brodehl J, Pichlmayr R (1984) Dosage of cyclosporin A in children with renal transplants. Clin Nephrol 22: 68–71
Hoyer PF (1990) Cyclosporin-A-Therapie bei Kindern nach Nierentransplantation. Kinderarzt 21: 325–329
Hoyer PF, Offner G, Oemar BS, Brodehl J, Ringe B, Pichlmayr R (1990) Four years' experience with cyclosporin A in pediatric kidney transplantation. Acta Paediatr Scand 79: 622–629
Thiru S (1989) Pathological effects of cyclosporin A in clinical practice. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Dordrecht, pp 324–364
Brodehl J, Hoyer PF, Oemar BS, Helmchen U, Wonigeit K (1988) Cyclosporin treatment of nephrotic syndrome in children. Transplant Proc 20 [Suppl 4]: 269–274
Brandis M, Burghard R, Leititis J, Zimmerhackl B, Hildebrandt F, Helmchen U (1988) Cyclosporin A for the treatment of nephrotic syndrome. Transplant Proc 20 [Suppl 4] 275–279
Capodicasa G, De Santo NG, Nuzzi F, Giordano G (1986) Cyclosporin A in nephrotic syndrome of childhood—a 14 months experience. Int Pediatr Nephrol 7: 69–72
Niaudet P, Tete MJ, Broyer M, Habib R (1988) Cyclosporin and childhood idiopathic nephrosis. Transplant Proc 20 [Suppl 4]: 265–268
Tejani A, Butt K, Trachtman H (1988) Cyclosporin A induced remission of relapsing nephrotic syndrome in children. Kidney Int 33: 729–734
Lagrue G, Laurent J, Belghiti D, Robeva R (1986) Cyclosporin and idiopathic nephrotic syndrome. Lancet II: 692–693
Meyrier A, Condamin MC, Simon P (1988) Treatment with cyclosporin of adult idiopathic nephrotic syndrome resistant to corticosteroids and other immuno-suppressants. Transplant Proc 20 [Suppl 4]: 259–261
Waldo FB, Kohaut EC (1987) Therapy of focal segmental glomerulosclerosis with cyclosporin. Pediatr Nephrol 1: 180–182
Brodehl J, Brandis M, Helmchen U, Hoyer PF, Burghard R, Ehrich JHH, Zimmerhackl RB, Klein W, Wonigkeit K (1988) Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis. Klin Wochenschr 66: 1126–1137
Graffenried B, Friend D, Shand N, Schiess W, Timonen P (1990) Cyclosporin (SandimmunR) in autoimmune disorders. In: Thomson AW (ed) Cyclosporin, mode of action and clinical applications. Kluwer, Dordrecht, pp 213–251
Niaudet P (1990) Steroid resistant idiopathic nephrotic syndrome and ciclosporine. Pediatr Nephrol 4: C52
Hoyer PF (1989) Cyclosporin A in MCNS: CsA study II of the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 3: C60
Mihatsch MJ, Bach JF, Coovadia HM, Forre O, Moutsopoulos HM, Drosis AA, Siamopoulos KL, Noel LH, Ramsaroop R, Hällgren R, Svenson K, Bohman SO (1988) Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 66: 43–47
Feutren G, Querin S, Noel LH, Chatenoud L, Beaurain G, Rron F, Lesavre P, Bach JF (1987) Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 111: 1063–1068
Miescher PA (1986) Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9: 271–282
Miescher PA, Favre H, Mihatsch MJ, Chatelanat F, Huang YP, Zubler R (1988) The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc 20: 224–237
Hoyer PF, Brodehl J (1988) Therapie von schwer verlaufendem systemischen Lupus erythematodes — Hoffnung durch Cyclosporin A? (abstract) Monatsschr Kinderheilkd 136: 516
Isenberg DA, Snaith ML, Morrow WJW, Al-Khader AA, Cohen SL, Fisher C, Mowbray J (1981) Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 3: 163–165
Ter Borg EJ, Tegzess AM, Kallenberg CGM (1988) Unexpected severe reversible cyclosporine A induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Clin Nephrol 29: 93–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoyer, P.F., Brodehl, J., Ehrich, J.H.H. et al. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 5, 630–638 (1991). https://doi.org/10.1007/BF00856658
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00856658